Akarna Therapeutics Gets $15M

San Diego- and Cambridge, England-based Akarna Therapeutics Ltd. announced this morning that it has raised $15M in a Series B funding round. The biopharmaceutials company, whch is working on treatments for non-alcoholic steatohepatitis (NASH), a fatty liver disease, said the funding came from Forbion Capital Partners, New Science Ventures, and Third Point Ventures. The new funding will go to fund proof-of-concept studies for the company's drug candidate. The company is led by Dr. Raju Mohan. More information »